Mexico Insulin Pens Market Overview, 2031

Key Insights

• According to the research report, "Mexico Insulin Pens Market Outlook, 2031," published by Bonafide Research, the Mexico Insulin Pens Market is anticipated to add to more than 170.28 Million by 2026-31.
• Mexico faces a high diabetes burden, with a national prevalence of 17.0% among adults per the ENSANUT Continua 2021–2024 survey, and approximately 14.12 million people aged 20-79 living with diabetes as of 2021.
• The Mexican smart insulin pen market is characterized by a unique product distribution, where first-generation pens (NFC tap-to-transfer dose logging) dominate at 61.7% of revenue. This is because they align with the cost structure and workflow simplicity preferred by Mexico's public health institutions, where clinicians review aggregated dose data at periodic visits.
• In a notable market development, Chinese biopharmaceutical company Ganlee obtained COFEPRIS approval in May 2024 to market its prefilled insulin glargine pen (BAGILIN) in Mexico, marking the company's entry into the market as a Marketing Authorization Holder (MAH) and potentially providing more affordable treatment options.
• In April 2024, COFEPRIS authorized a continuous micro-infusion insulin pump for patients over seven years of age diagnosed with type 1 diabetes, expanding the range of advanced insulin delivery devices available in the country.

Market Outlook

• The Mexican insulin pens market is poised for significant growth, driven by the escalating burden of type 2 diabetes, the progressive expansion of connected insulin pen prescriptions within public health protocols (IMSS and ISSSTE), and the entry of updated next-generation platforms from major companies. The smart insulin pens segment alone is expected to grow from USD 1.81 Million in 2025 to USD 4.93 Million by 2035, reflecting strong adoption.
• Home care settings are expected to register the fastest growth in smart insulin pen adoption at an, as the chronic nature of diabetes care and the connectivity features of smart pens enable dose tracking and remote clinician access from home, shifting management away from clinical settings.
• Key companies in this market include Novo Nordisk, Medtronic, Sanofi, and Becton Dickinson (BD), alongside newer entrants like Ganlee. Key regulatory bodies and associations include the Federal Commission for the Protection against Sanitary Risks (COFEPRIS) and the Mexican Social Security Institute (IMSS).

Market Dynamics

Driver: High diabetes prevalence and institutional adoption
The primary driver is Mexico's high and growing diabetes burden. With a national prevalence of 17.0%, there is immense demand for effective insulin delivery methods. This is further amplified by the progressive integration of connected insulin pens into the diabetes care protocols of major public health institutions like IMSS and ISSSTE, which serve as the primary channels for device distribution and adoption.
Challenge: Cost and access disparities
A significant challenge is the high cost associated with advanced insulin pen devices, which limits affordability for a large segment of the patient population. This is compounded by limited access to healthcare services in certain regions of Mexico, creating disparities in treatment availability and adoption.
Trend: Regulatory streamlining and entry of affordable alternatives
A key trend is the evolution of the regulatory landscape. In September 2025, COFEPRIS introduced an abbreviated regulatory pathway that accepts existing FDA and EU MDR approvals within a 30-day review cycle, removing a barrier that historically delayed new product launches by six months or more. This, combined with the entry of new players like Ganlee offering potentially more cost-effective alternatives, is expected to increase competition and improve product accessibility.

Mexico Insulin Pens Devices Procurement and Industry Impact

• COFEPRIS Registration: All insulin pens and delivery devices must obtain a health registration (registro sanitario) from the Federal Commission for the Protection against Sanitary Risks (COFEPRIS) before they can be legally imported, sold, or distributed in Mexico.
• Abbreviated Regulatory Pathway (Effective September 2025): COFEPRIS has introduced an expedited review process that accepts existing approvals from the U.S. FDA and the EU MDR, with a target review cycle of 30 days. This is designed to accelerate the availability of new and advanced insulin pen technologies in the Mexican market.
• Institutional Protocol Integration: For widespread adoption, insulin pen devices often need to be integrated into the treatment protocols and formularies of major public health institutions, such as the Mexican Social Security Institute (IMSS) and the Institute for Social Security and Services for State Workers (ISSSTE), which are dominant players in the healthcare system.
• Adherence to Import/Export Regulations: Manufacturers and importers must comply with all applicable import/export trade statistics and regulations, including proper labeling, to ensure traceability and prevent the circulation of counterfeit devices.

Segment Analysis

Mexico Insulin Pens Devices By Product Type
• Smart insulin pens are the most technologically advanced segment, integrating Bluetooth connectivity, NFC tap-to-transfer dose logging, dose memory, and compatibility with diabetes management applications. This segment is expected to grow from USD 1.81 Million in 2025 to USD 4.93 Million by 2035. The market is dominated by first-generation NFC-based pens (61.7% revenue share) due to their alignment with the workflow and cost requirements of Mexico's public health institutions, which prefer reviewing aggregated data at clinic visits rather than real-time monitoring. Next-generation Bluetooth-enabled pens are anticipated to gain traction as institutional protocols evolve.
• Disposable (prefilled) insulin pens are widely used for their convenience and simplified dosing process, eliminating the need for cartridge loading. They are particularly beneficial for newly diagnosed patients, older adults, and those with limited dexterity. The market for cartridges used in reusable pens represents another key sub-segment.

Mexico Insulin Pens Devices By Disease/Indication Type
• Type 1 diabetes represents a highly insulin-dependent segment where insulin pens have become an important tool for daily disease management. Multiple daily injection therapy requires precise dose adjustments, and insulin pens provide improved dosing accuracy, portability, and convenience compared with traditional syringe-based administration. Pediatric endocrinology clinics increasingly recommend pen devices to improve treatment compliance among children and adolescents.
• Type 2 diabetes represents the largest indication segment for insulin pens in Mexico because of the country's high prevalence of obesity and metabolic disorders. As patients progress beyond oral antidiabetic medications, insulin pens simplify therapy initiation and encourage better adherence through easier administration and discreet use. Healthcare providers increasingly prefer pen-based insulin delivery because it improves patient confidence while reducing dosing errors.

Mexico Insulin Pens Devices By End-User
• Homecare remains the largest end-user segment as most insulin therapy in Mexico is managed outside hospitals. Insulin pens enable patients to administer doses independently with minimal preparation, allowing better adherence to prescribed treatment schedules. Their compact design supports insulin administration at work, school, or during travel, making them particularly valuable for active individuals living with diabetes.
• Hospitals utilize insulin pens primarily for inpatient diabetes management, perioperative glucose control, and stabilization of patients experiencing diabetes-related complications. Hospital pharmacists and nursing staff follow standardized medication administration protocols to ensure safe insulin delivery while educating patients on proper pen use before discharge, facilitating a smoother transition to home-based care.
• Ambulatory care centers, diabetes clinics, and endocrinology practices play an increasingly important role in insulin initiation and follow-up management. These facilities provide individualized dose titration, injection training, and patient education programs that improve confidence in insulin pen use. As outpatient diabetes services continue to expand across Mexico, ambulatory care is becoming an important channel for promoting long-term adherence and optimized glycemic management.

Mexico Insulin Pens Devices By Distribution Channel
• Retail pharmacies represent the largest distribution channel for insulin pens in Mexico because they provide convenient access to diabetes medications across both urban and semi-urban areas. Large pharmacy chains and independent community pharmacies play an important role in dispensing insulin pens, educating patients on injection techniques, and ensuring continuity of therapy through prescription refills. Pharmacists increasingly assist patients in selecting compatible pen needles, explaining storage requirements, and promoting adherence to prescribed insulin regimens.
• Hospital pharmacies remain an essential distribution channel for insulin pens used in inpatient diabetes management, emergency care, and treatment of diabetes-related complications. Public institutions, including facilities under IMSS (Instituto Mexicano del Seguro Social) and ISSSTE (Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado), procure insulin pens through centralized purchasing systems to ensure consistent availability.
• Online retail is an emerging distribution channel as digital healthcare adoption and e-commerce continue to expand throughout Mexico. Licensed online pharmacies offer prescription management, home delivery services, automatic refill options, and virtual pharmacist consultations, improving convenience for patients requiring long-term insulin therapy. Online purchasing is particularly beneficial for individuals in remote or underserved regions where access to specialty diabetes products may be limited.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Insulin Pens Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Reusable Insulin Pens
• Disposable/Prefilled Insulin Pens
• Smart/Connected Insulin Pens

By Disease/Indication Type
• Type 1 Diabetes
• Type 2 Diabetes

By End-User
• Home/Self Administration
• Hospitals & Clinics
• Ambulatory Care

By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online retail